HOME > TRENDS
TRENDS
-
Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
-
Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
-
Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
-
15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
-
Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
-
Top 10 PHARMA JAPAN Articles in 2020
December 28, 2020
-
51 Drugs Listed in 2019 with Total Peak Sales Forecast of 370 Billion Yen, Many for Orphan Diseases
December 27, 2019
-
Top 10 PHARMA JAPAN Articles in 2019
December 26, 2019
-
Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
-
Chugai Running Offensive/Defensive Play towards EPS Growth Goal, Hemlibra Outpaces Target
August 9, 2019
-
Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
-
Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
-
Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
-
12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
-
Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
June 18, 2019
-
Female Manager Ratios at Foreign Drug Makers Rising in Japan, 7 Out of 10 Log 20%-Plus
May 28, 2019
-
Cancer Drugs Underpin Big Pharmas’ Japan Revenue in 2018
April 25, 2019
-
Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
March 5, 2019
-
Industry Workforce Dwindling as More and More Staffers Take Voluntary Retirement; Astellas Could Cut 700 Jobs
February 22, 2019
-
Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
February 12, 2019
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…